Compare Deutsche Bank AG (DB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Summit Therapeutics Inc — how do they compare? Deutsche Bank AG trades at $38.38 (market cap $71.96B), while Summit Therapeutics Inc trades at $15.34 (market cap $12.06B). The key difference: Deutsche Bank AG is far larger — about 6× Summit Therapeutics Inc's market cap, and Deutsche Bank AG pays a 3.04% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DB | SMMT | |
|---|---|---|
Market Cap | $71.96B | $12.06B |
Sector | Financials | Health |
52-Week High | $40.33 | $26.98 |
52-Week Low | $28.37 | $12.55 |
Dividend Yield | 3.04% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $38.27, up 0.55% today, with a bullish technical signal from moving averages. The stock shows a discounted valuation with a P/E of 10.07 and P/B of 0.79. Recent Q2 2026 earnings missed expectations at $0.66 per share versus $0.91, but revenue growth remains solid. The company announced a $1.00 dividend and a new share buyback program, supported by strong capital buffers and its recent designation as a clearing bank for China's renminbi (Reuters, 2026-08-10).
The outlook is mixed; strong operational performance and strategic initiatives like AI dealmaking (CNBC, 2026-07-29) offer upside, but earnings volatility and regulatory scrutiny (Reuters, 2026-07-22) pose risks. Analyst consensus is neutral with 57.58% hold ratings, reflecting cautious optimism amid execution challenges.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
